Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats

Hypertens Res. 2006 Dec;29(12):1021-7. doi: 10.1291/hypres.29.1021.

Abstract

Hypertension due to chronic inhibition of NO synthase (NOS) by Nomega-nitro-L-arginine methyl ester (L-NAME) administration is characterized by both impaired NO-dependent vasodilation and enhanced sympathetic vasoconstriction. The aim of our study was to evaluate changes in the participation of major vasoactive systems in L-NAME-treated rats which were subjected to simultaneous antihypertensive (captopril) or antioxidant (N-acetylcysteine, NAC) treatment. Three-month-old Wistar males treated with L-NAME (60 mg/kg/day) for 5 weeks were compared to rats in which L-NAME treatment was combined with simultaneous chronic administration of captopril or NAC. Basal blood pressure (BP) and its acute responses to consecutive i.v. injections of captopril (10 mg/kg), pentolinium (5 mg/kg), L-NAME (30 mg/kg), tetraethylammonium (TEA, 16 mg/kg) and nitroprusside (NP, 20 microg/kg) were determined in conscious rats at the end of the study. The development of L-NAME hypertension was prevented by captopril treatment, whereas NAC treatment caused only a moderate BP reduction. Captopril treatment normalized the sympathetic BP component and significantly reduced residual BP (measured at full NP-induced vasodilation). In contrast, chronic NAC treatment did not modify the sympathetic BP component or residual BP, but significantly enhanced NO-dependent vasodilation. Neither captopril nor NAC treatment influenced the compensatory increase of TEA-sensitive vasodilation mediated by endothelium-derived hyperpolarizing factor in L-NAME-treated rats. Chronic captopril treatment prevented L-NAME hypertension by lowering of sympathetic tone, whereas chronic NAC treatment attenuated L-NAME hypertension by reduction in the vasodilator deficit due to enhanced NO-dependent vasodilation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / pharmacology
  • Acetylcysteine / therapeutic use*
  • Animals
  • Antihypertensive Agents / pharmacology
  • Antihypertensive Agents / therapeutic use*
  • Blood Pressure / drug effects
  • Captopril / pharmacology
  • Captopril / therapeutic use*
  • Hypertension / chemically induced
  • Hypertension / prevention & control*
  • Male
  • NG-Nitroarginine Methyl Ester / antagonists & inhibitors
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitroprusside / pharmacology
  • Nitroprusside / therapeutic use
  • Pentolinium Tartrate / pharmacology
  • Pentolinium Tartrate / therapeutic use
  • Rats
  • Rats, Wistar
  • Tetraethylammonium / pharmacology
  • Tetraethylammonium / therapeutic use

Substances

  • Antihypertensive Agents
  • Nitroprusside
  • Tetraethylammonium
  • Pentolinium Tartrate
  • Captopril
  • NG-Nitroarginine Methyl Ester
  • Acetylcysteine